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OBSERVATION

Intrafamilial Phenotypic Variability
in Friedreich Ataxia Associated
With a G130V Mutation in the FRDA Gene
Dominick J. H. McCabe, MRCPI; Nicholas W. Wood, FRCP; Fergus Ryan, PhD; Michael G. Hanna, MD;
Sean Connolly, MD; David P. Moore, MRCPI; Janice Redmond, MD;
David E. Barton, PhD; Raymond P. Murphy, FRCP

Background: Most patients with Friedreich ataxia (FA)
have a GAA trinucleotide repeat expansion in intron 1
of the FA gene (FRDA) on both arms of chromosome 9.
However, some patients are compound heterozygotes and
harbor a GAA expansion on one allele and a point mutation on the other. Compound heterozygous patients with
FA who have a GAA expansion and a G130V mutation
have been reported to have an atypical phenotype with
a slow disease progression, minimal or no ataxia, or gait
spasticity.
Objective: To describe intrafamilial phenotypic variability in a GAA expansion/G130V mutation compound
heterozygous family with FA.
Setting: Tertiary referral university hospital setting.
Patients and Methods: A 34-year-old man presented to our hospital with a 24-year history of stiff legs
and mild unsteadiness of gait. Clinical examination
showed a spastic paraparesis with normal to pathologically brisk deep tendon reflexes and mild left upper limb
ataxia. His 27-year-old sister presented with a slowly pro-
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gressive early-onset ataxic syndrome. She had ataxia of
gait, mild to severe limb ataxia, and reduced or absent
deep tendon reflexes, but no evidence of spasticity on
examination.
Results: Neurophysiologic investigations showed evi-

dence of a sensory axonal neuropathy, and molecular genetic analysis showed that both siblings were compound heterozygotes with a GAA expansion and a G130V
mutation.
Conclusions: This report confirms that compound heterozygous patients with FA who have a GAA expansion
and a G130V mutation may present with an ataxic phenotype and that intrafamilial phenotypic variability in
these pedigrees can occur. It also emphasizes the importance of performing molecular genetic analysis for the
GAA trinucleotide expansion in patients presenting with
a spastic paraparesis of undetermined etiology, especially when there is neurophysiologic evidence of a sensory axonal neuropathy.

Arch Neurol. 2002;59:296-300

RIEDREICH ATAXIA (FA) is a
progressive neurodegenerative disorder with a prevalence of approximately 1 in
50000 in European populations.1 According to Harding’s mandatory clinical diagnostic criteria for FA, affected individuals should have an age at
onset younger than 25 years and definitely younger than 27 years, ataxia of gait,
ataxia of all 4 limbs, lower limb areflexia,
and a mode of inheritance consistent with
an autosomal recessive disorder.2,3 Dysarthria was present in all patients with a
disease duration of at least 10 years, and
96% of patients had neurophysiologic
evidence of a sensory axonal neuropathy
in Harding’s original series.2 The majority of patients with FA, including some
individuals with an atypical phenotype,
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have a GAA trinucleotide repeat expansion in intron 1 of the FA gene (FRDA) on
both arms of chromosome 9q 13-21.1.1,3-5
Normal alleles contain between 6 and 34
GAA repeats, whereas FA alleles carry between 66 and 1700 repeats.1,3,4,6,7 Some individuals are compound heterozygotes with
a GAA trinucleotide repeat expansion on
one allele and a point mutation on the
other,3,4,7-12 and Bidichandani and colleagues8 identified one such missense mutation, the G130V mutation, in exon 4 of
the FRDA gene in 1997. Although the phenotype may vary between family members harboring 2 GAA expansions,3,13 intrafamilial phenotypic variability has rarely
been described in compound heterozygous FA pedigrees with a GAA expansion
on one allele and a G130V mutation on the
other.8,9

WWW.ARCHNEUROL.COM

Downloaded from www.archneurol.com at IREL, on August 11, 2010
©2002 American Medical Association. All rights reserved.

REPORT OF CASES

A

I

CASE 1
A 34-year-old right-handed man (subject III:1; Figure,
A) presented to our hospital with a 24-year history of stiff
legs and unsteadiness while walking; his clinical history
has been briefly alluded to previously.3 He was the offspring of two unrelated Irish parents who had no symptoms of ataxia or neurologic disease.
He had been well until 10 years of age, when he
developed a febrile illness with vomiting, nocturnal
confusion, agitation, and arthralgia during a 3-week
period. He was treated with a course of oral amoxicillin,
and although his symptoms improved within weeks, he
complained of lower limb aching pains for the following 2 months. Subsequently, he noted stiffness in both
legs and incoordination of the left more than right leg,
with difficulty correcting his posture if pushed over. He
had no subjective limb weakness, sensory symptoms, or
sphincter disturbance. The unsteadiness while walking
gradually increased, so that he required assistance to
walk within 6 years and began using crutches 10 years
after symptom onset. Although his leg stiffness subjectively increased during the 5-year period before the current examination, he was still ambulatory with the aid
of 2 crutches. He had no cardiac symptoms and no
history of diabetes and was not taking any medication
at the time of assessment. One of his sisters had been
given a clinical diagnosis of FA at 20 years of age (patient III:2), but there was no other family history of
ataxia.
General physical examination disclosed a very mild
thoracic scoliosis, fixed flexion contractures at the left
knee and hip joints, and pes planus, but was otherwise
normal. The findings on neurologic examination are outlined in the Table; the patient had a spastic paraparesis
with normal to pathologically brisk reflexes throughout, bilateral extensor plantar responses, and minimal
ataxia. He did not fulfill all of Harding’s mandatory clinical diagnostic criteria for FA, and he did not have dysarthria 24 years after disease onset.
Results of routine hematologic and biochemical investigations were normal, as were levels of blood glucose, vitamin E, vitamin B12, and folate. Thyroid function test results, autoantibody screening results, and
treponemal serologic findings were normal or negative.
His electrocardiogram was generally of low amplitude and
showed p mitrale, but was otherwise normal, and a 2-dimensional transthoracic echocardiogram was normal.
Magnetic resonance images of the brain were normal, but
magnetic resonance images of the cervical spine showed
a right-sided posterior disc protrusion at C4-5, posteriorly displacing the cord at this level, but without evidence of signal abnormality within the cord.
CASE 2
The sister (subject III:2; Figure, A) of subject III:1 was
assessed at 27 years of age. She had had normal developmental milestones, but had transient ataxia and vomiting for a few days associated with a febrile illness at 5
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A, Family tree of the compound heterozygous patients with Friedreich ataxia
(subjects III:1 and III:2). Squares indicate males; circles, females; horizontal
line above symbols, examined family members; diagonal slash, deceased;
shading, G130V mutation; solid sections, GAA expansion; and arrow, index
case with the G130V mutation. Some unaffected family members are
represented as triangles to preserve anonymity. Asterisk indicates GAA
repeat number within normal range and G130V point mutation testing
negative. B, The 2.5% agarose gel showing polymerase chain reaction
amplification products from the G130V mutation analysis of the pedigree.
M indicates 100–base pair (bp) ladder showing 3 size markers of 100, 200,
and 300 bp. The positions of the 104-bp and 77-bp fragments are indicated
on the right.

years of age. Ten years later, she developed a sore throat,
arthralgia, and fever and was diagnosed as having rheumatic fever. Subsequent to this illness, she had mild persistent left leg weakness and mild ataxia of gait, but was
able to run and continued to play sports. The ataxia of
gait increased slowly until 19 years of age, and after a recurrence of rheumatic fever at 20 years of age, she was
clinically diagnosed as having FA. Her unsteadiness while
walking increased during the 7-year period before presentation, but she was still able to walk without assistance at the time of assessment.
General physical examination showed a mild thoracic scoliosis and left pes cavus, but was otherwise normal. Her neurologic findings are outlined in the Table.
In contrast to her clinically affected brother (subject III:
1), she had no evidence of spasticity or limb weakness,
and she had reduced or absent deep tendon reflexes and
more pronounced ataxia of gait and limbs. It was of interest that she did not have dysarthria at least 12 years
after disease onset either.
WWW.ARCHNEUROL.COM
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Clinical Characteristics of the 2 Affected Patients
Clinical Details
Age at examination, y
Disease duration, y
Gait
Titubation
OA/SP*
Nystagmus
Dysarthria
Upper limb tone
Lower limb tone
Pyramidal weakness
Upper limb reflexes
Lower limb reflexes
Extensor plantar response
Upper limb ataxia
Lower limb ataxia
Cerebellar rebound
Sensation in upper limbs
Sensation in lower limbs
Distal amyotrophy
Pes cavus
Nerve conduction studies

Subject III:1

Subject III:2

34
24
Spastic scissoring
No
Right SP
Very mild horizontal gaze–evoked
No
Normal
Severe spasticity
Not in arms/severe in legs
++ to +++
++++ Right and left knee jerks,
+++ left ankle jerk/++ right ankle jerk
Bilateral
Mild left
Indeterminate; spasticity
Bilateral
Impaired vibration
Impaired pinprick, temperature, vibration
Legs
No; pes planus
Sensory axonal neuropathy

27
12†
Ataxic
Mild
No
No; jerky pursuit movements
No
Normal
Normal
No
Absent
+ Right knee jerk (reinforced),
absent left knee/ankle jerks
Bilateral
Mild right and left
Severe right and left
Bilateral
Normal
Impaired vibration and joint position
No
Left and varus deformity
Sensory axonal neuropathy

*OA indicates optic atrophy; SP, suspicious pallor of the optic disc; +, reduced deep tendon reflex; ++, normal deep tendon reflex; +++, brisk deep tendon reflex;
and ++++, brisk deep tendon reflex with clonus. Subject III:2 was considered to have had an age at onset of the disease at 15 years because of the presence of
persistent symptoms after this age.
†Subject III:2 was considered to have onset at age 15 years because of the presence of persistent symptoms after this age.

Results of routine hematologic and biochemical investigations were normal, and levels of blood glucose, vitamin B12, and folate and treponemal serologic findings
were normal or negative. Vitamin E levels were mildly
reduced at 10.7 µmol/L (reference range, 11.5-35 µmol/L).
An electrocardiogram showed T-wave inversion in leads
III and V1, but no other signs of cardiomyopathy. Twodimensional transthoracic echocardiography at age 23
years had shown concentric left ventricular hypertrophy with good left ventricular function.
MOLECULAR GENETIC ANALYSIS
In view of the clinical diagnosis of FA in subject III:2,
polymerase chain reaction (PCR) analysis for the GAA
trinucleotide repeat expansion was performed by means
of established techniques.3,5,14 Subject III:1 was estimated
to have approximately 954 GAA repeats and subject III:2
was estimated to have 917 GAA repeats on one allele of
chromosome 9, but the GAA repeat number on the
other allele was normal in both subjects. The diffuse
PCR product associated with the GAA expansion in subject III:2 overlapped the expansion in subject III:1 on
agarose gel electrophoresis (data not shown). Because
both patients were presumed to be compound heterozygotes, G130V point mutation testing was performed
with the following primers: FRDA G130Vf: 5⬘-AAGCAATGATGACAAAGTGCTAAC; FRDA G130Vr:
5⬘-CTCCACCCAGTTTGACAGTTAAGTCA. The 25-µL
reaction contained 200 ng of DNA, 100 ng of each
primer, 200µM deoxynucleotide mixture (dNTP), and
standard PCR buffer containing 1.5mM magnesium
chloride and 1 U of Taq polymerase (Gibco BRL, Life
(REPRINTED) ARCH NEUROL / VOL 59, FEB 2002
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Technologies, Paisley, Scotland). The PCR conditions
were 94°C for 5 minutes; followed by 35 cycles of 30
seconds at 94°C, 59°C, and 72°C, respectively, and a
final extension at 72°C for 5 minutes. The underlined T
in the FRDA G130Vr primer results in the generation of
a HincII site in the presence of the G130V mutation.
After PCR, 10 µL of the PCR product was digested for a
minimum of 2 hours with 10 U of HincII (New England
Biolabs Inc, Beverly, Mass) with the use of conditions
recommended by the manufacturer. The digestion products were visualized on a 2.5% agarose gel containing
ethidium bromide, 0.5 µg/µL (Figure, B). Wild-type
sequences from subjects not carrying the G130V mutation result in an uncut PCR product of 104 base pairs
(bp). The G130V mutation results in 2 additional products of 77 and 27 bp, but the 27-bp product is generally
not visible on the agarose gel. This analysis showed a
G130V mutation within exon 4 of the FRDA gene in
both patients (subjects III:1 and III:2). Subsequent
screening of the unaffected parents confirmed that the
father (subject II:1) was a carrier of the GAA expansion
and the mother (subject II:2) carried the G130V mutation. The remaining sibling (subject III:3) was phenotypically and genotypically normal.
COMMENT

The first family reported to be heterozygous for the GAA
trinucleotide repeat expansion and a G130V mutation
exhibited an atypical FA phenotype.8 Although the clinical details of the 3 affected members were not published
in detail, the 2 older siblings presented with leg weakness in the early teens, with a gradual disease progresWWW.ARCHNEUROL.COM
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sion so that they were able to walk with assistance at least
20 years after disease onset. They did not have dysarthria, they had minimal or no ataxia, and their deep tendon reflexes were either reduced or absent. The authors
reported “little intrafamilial phenotypic variation.” A subsequent collaborative study of the phenotypic expression of compound heterozygous patients with FA included 6 patients from 3 families who were compound
heterozygotes with a GAA expansion and a G130V mutation.9 Four of these 6 patients had a more spastic than
ataxic gait. There was some intrafamilial phenotypic variability in one family with 2 affected siblings, in which
one sibling had mild gait ataxia, retained upper limb reflexes, and brisk knee jerks, whereas the other had a spastic gait without ataxia, retained upper limb reflexes, and
absent lower limb reflexes. Ataxia of the limbs was not
commented on in that article. Two recent reviews have
emphasized that compound heterozygotes harboring a
GAA expansion and a G130V mutation all have an atypical FA phenotype, but they stated that all patients have
brisk knee reflexes7 or a spastic gait.15
We report an additional compound heterozygous FA
family with a GAA trinucleotide repeat expansion on one
allele and a G130V mutation on the other allele of chromosome 9. This is the second report of a G130V mutation in a family of Irish descent with FA, and all cases
described to date are of European origin (Irish, English,
or French).16 Although the difference in disease duration between the 2 affected siblings may have influenced the clinical findings, there was definite intrafamilial phenotypic variability in this family, with a more spastic
than ataxic phenotype in the brother (subject III:1) and
a more ataxic phenotype, without limb spasticity, in the
sister (subject III:2). The presence of cervical cord compression on magnetic resonance imaging may have contributed to the spastic paraparesis in subject III:1, but this
finding would not account for the preservation of deep
tendon reflexes that are typically absent in the lower limbs
in FA. If the phenotype had been consistent within the
family, one would have expected lower limb hyporeflexia or areflexia in subject III:1 at 24 years after disease
onset, in view of these findings in his younger sibling earlier in her disease course. Conversely, one cannot completely exclude the possibility that borderline vitamin E
deficiency contributed to a more pronounced ataxic phenotype with hyporeflexia or areflexia in subject III:2.17
This patient is unavailable for follow-up, so we cannot
comment on whether her clinical condition has stabilized with vitamin E replacement therapy. However, because the size of the GAA trinucleotide repeat expansion in peripheral blood lymphocytes was comparable in
the 2 affected siblings, the variation in phenotype is most
likely to be secondary to somatic mosaicism in the size
of the GAA expansion.18 The influence of other modifier genes cannot be excluded.
The GAA trinucleotide repeat expansion is believed
to interfere with messenger RNA transcription in the FRDA
gene,4,8,19 thus leading to reduced levels of functional
frataxin protein in affected individuals. The extent of reduction in the levels of frataxin appears to be inversely proportional to the size of the expansion.9 It has been proposed that the G130V mutation leads to the production
(REPRINTED) ARCH NEUROL / VOL 59, FEB 2002
299

of an abnormal frataxin protein with modified or reduced function.9 The resulting combination of “frataxin
deficiency,” caused by a GAA expansion, and “frataxin dysfunction,” secondary to a G130V mutation, may account
for the difference in phenotypic expression between patients with FA who are compound heterozygotes with a
GAA expansion and a G130V mutation and those with 2
GAA expansions. In addition, the degree of frataxin dysfunction may vary depending on the point mutation present in the FRDA gene. It has been postulated that the
G130V mutation causes more subtle loss of frataxin function than another missense mutation (I154F) that is associated with a typical FA phenotype.8
Although compound heterozygotes with FA who
have a GAA expansion and a G130V mutation commonly present with a predominantly spastic phenotype,
this report confirms that these patients may present with
an ataxic phenotype instead, with reduced or absent deep
tendon reflexes. In addition, intrafamilial phenotypic variability in these pedigrees may occur. It also emphasizes
the importance of performing molecular genetic analysis for the GAA trinucleotide repeat expansion in patients presenting with a spastic paraparesis of undetermined etiology, especially when there is neurophysiologic
evidence of sensory axonal neuropathy that is typically
seen in FA.
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